Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S. Capasso A, et al. Among authors: leong s. Anticancer Drugs. 2018 Oct;29(9):827-838. doi: 10.1097/CAD.0000000000000673. Anticancer Drugs. 2018. PMID: 30048249 Free PMC article.
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. Camidge DR, et al. Among authors: leong s. Anticancer Drugs. 2008 Jan;19(1):77-84. doi: 10.1097/CAD.0b013e3282f077b3. Anticancer Drugs. 2008. PMID: 18043132 Clinical Trial.
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. O'Bryant CL, et al. Among authors: leong s. Cancer Chemother Pharmacol. 2009 Feb;63(3):477-89. doi: 10.1007/s00280-008-0761-3. Epub 2008 May 29. Cancer Chemother Pharmacol. 2009. PMID: 18509645 Free PMC article.
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Olsen CC, et al. Among authors: leong s. Am J Clin Oncol. 2009 Apr;32(2):115-21. doi: 10.1097/COC.0b013e318180baa3. Am J Clin Oncol. 2009. PMID: 19307945 Clinical Trial.
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Leong S, et al. J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652058 Clinical Trial.
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Spratlin JL, et al. Among authors: leong s. J Clin Oncol. 2010 Feb 10;28(5):780-7. doi: 10.1200/JCO.2009.23.7537. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048182 Free PMC article. Clinical Trial.
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR. Zhou Q, et al. Among authors: leong s. Invest New Drugs. 2011 Apr;29(2):340-6. doi: 10.1007/s10637-009-9383-9. Epub 2010 Jan 19. Invest New Drugs. 2011. PMID: 20084425 Free PMC article. Clinical Trial.
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG. Pitts TM, et al. Among authors: leong s. Clin Cancer Res. 2010 Jun 15;16(12):3193-204. doi: 10.1158/1078-0432.CCR-09-3191. Epub 2010 Jun 8. Clin Cancer Res. 2010. PMID: 20530704 Free PMC article.
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG. Tentler JJ, et al. Among authors: leong s. Mol Cancer Ther. 2010 Dec;9(12):3351-62. doi: 10.1158/1535-7163.MCT-10-0376. Epub 2010 Oct 5. Mol Cancer Ther. 2010. PMID: 20923857 Free PMC article.
1,522 results